Close Menu

ALS

CNN reports that an experimental treatment is showing promise for treating the genetic form of amyotrophic lateral sclerosis.

The ALS Association is committing $3.5 million, including a $1 million commitment from its Greater New York chapter, while the Tow Foundation is contributing $2.5 million.

New Scientist reports that researchers have tested an ALS gene therapy in a mouse model of disease.

The assay was shown to have a simpler workflow and was able to detect mosaicism, with only a slight decrease in sensitivity compared to a lab-developed test.

The New York Genome Center created MetroNome as a way to show genomic data in the context of phenotypes, but integration challenges lie ahead.

Silicon Valley VC firm DFJ led the investment in Verge, which is applying machine learning to the development of new drugs for Parkinson's and ALS.

Using large-scale GWAS data, researchers saw shared genetic contributors for ALS and frontotemporal dementia, as well as ALS and progressive supranuclear palsy.

Amarantus has reacquired LymPro Test, MSPrecise, and NuroPro and said that it plans to assign the assets to a new subsidiary.

Both a genome-wide association study and a rare variant burden analysis homed in on a role for KIF5A mutations in amyotrophic lateral sclerosis.

CRISPR Hopes for ALS

Gizmodo wonders whether CRISPR could present a treatment for amyotrophic lateral sclerosis.

Pages

Researchers are sampling the wild relatives of modern crops to try to preserve genetic diversity, NPR reports.

MIT's Search for Extraterrestrial Genomes is developing sequencing tools to use to try to detect whether there is any life on Mars, Quartz reports.

Undark reports on a bill introduced this year to the US House of Representatives to strengthen scientific integrity.

In Genome Research this week: post-zygotic mutations in diabetes development, single-cell RNA sequencing study of aging, and more.